Cracking the combination: Gut hormones for the treatment of obesity and diabetes

被引：29

作者：

Alexiadou, Kleopatra ^{[1
]}

Anyiam, Oluwaseun ^{[1
]}

Tan, Tricia ^{[1
]}

机构：

[1] Imperial Coll London, Sect Invest Med, London, England

来源：

JOURNAL OF NEUROENDOCRINOLOGY | 2019年 / 31卷 / 05期

基金：

英国生物技术与生命科学研究理事会;

关键词：

GLUCAGON-LIKE PEPTIDE-1; DEPENDENT INSULINOTROPIC POLYPEPTIDE; FOOD-INTAKE; ENERGY-INTAKE; CARDIOVASCULAR OUTCOMES; CORRECTS OBESITY; GLP-1; RECEPTORS; MESSENGER-RNA; WEIGHT-LOSS; 7-36; AMIDE;

D O I：

10.1111/jne.12664

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Obesity and type 2 diabetes are a veritable global pandemic. There is an imperative to develop new therapies for these conditions that can be delivered at scale to patients, which deliver effective and titratable weight loss, amelioration of diabetes, prevention of diabetic complications and improvements in cardiovascular health. Although agents based on glucagon-like peptide-1 (GLP-1) are now in routine use for diabetes and obesity, the limited efficacy of such drugs means that newer agents are required. By combining the effects of GLP-1 with other gut and metabolic hormones such as glucagon (GCG), oxyntomodulin, glucose-dependent insulinotropic peptide (GIP) and peptide YY (PYY), we may obtain improved weight loss, increased energy expenditure and improved metabolic profiles. Drugs based on dual agonism of GLP1R/GCGR and GLP1R/GIPR are being actively developed in clinical trials. Triple agonism, for example with GLPR1/GCGR/GIPR unimolecular agonists or using GLP-1/oxyntomodulin/PYY, is also being explored. Multi-agonist drugs seem set to deliver the next generation of therapies for diabetes and obesity soon.

引用

页数：8

共 92 条

[1] Weight and Metabolic Outcomes 12 Years after Gastric Bypass [J].

Adams, Ted D. ;

Davidson, Lance E. ;

Litwin, Sheldon E. ;

Kim, Jaewhan ;

Kolotkin, Ronette L. ;

Nanjee, M. Nazeem ;

Gutierrez, Jonathan M. ;

Frogley, Sara J. ;

Ibele, Anna R. ;

Brinton, Eliot A. ;

Hopkins, Paul N. ;

McKinlay, Rodrick ;

Simper, Steven C. ;

Hunt, Steven C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (12) :1143-1155

[2] HUMAN DISTRIBUTION AND RELEASE OF A PUTATIVE NEW GUT HORMONE, PEPTIDE-YY [J].

ADRIAN, TE ;

FERRI, GL ;

BACARESEHAMILTON, AJ ;

FUESSL, HS ;

POLAK, JM ;

BLOOM, SR .

GASTROENTEROLOGY, 1985, 89 (05) :1070-1077

[3] Health Effects of Overweight and Obesity in 195 Countries over 25 Years [J].

Afshin, Ashkan ;

Forouzanfar, Mohammad H. ;

Reitsma, Marissa B. ;

Sur, Patrick ;

Estep, Kara ;

Lee, Alex ;

Marczak, Laurie ;

Mokdad, Ali H. ;

Moradi-Lakeh, Maziar ;

Naghavi, Mohsen ;

Salama, Joseph S. ;

Vos, Theo ;

Abate, Kalkidan H. ;

Abbafati, Cristiana ;

Ahmed, Muktar B. ;

Al-Aly, Ziyad ;

Alkerwi, Ala'a ;

Al-Raddadi, Rajaa ;

Amare, Azmeraw T. ;

Amberbir, Alemayehu ;

Amegah, Adeladza K. ;

Amini, Erfan ;

Amrock, Stephen M. ;

Anjana, Ranjit M. ;

Arnlov, Johan ;

Asayesh, Hamid ;

Banerjee, Amitava ;

Barac, Aleksandra ;

Baye, Estifanos ;

Bennett, Derrick A. ;

Beyene, Addisu S. ;

Biadgilign, Sibhatu ;

Biryukov, Stan ;

Bjertness, Espen ;

Boneya, Dube J. ;

Campos-Nonato, Ismael ;

Carrero, Juan J. ;

Cecilio, Pedro ;

Cercy, Kelly ;

Ciobanu, Liliana G. ;

Cornaby, Leslie ;

Damtew, Solomon A. ;

Dandona, Lalit ;

Dandona, Rakhi ;

Dharmaratne, Samath D. ;

Duncan, Bruce B. ;

Eshrati, Babak ;

Esteghamati, Alireza ;

Feigin, Valery L. ;

Fernandes, Joao C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (01) :13-27

[4] Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial [J].

Ahmann, Andrew J. ;

Capehorn, Matthew ;

Charpentier, Guillaume ;

Dotta, Francesco ;

Henkel, Elena ;

Lingvay, Ildiko ;

Holst, Anders G. ;

Annett, Miriam P. ;

Aroda, Vanita R. .

DIABETES CARE, 2018, 41 (02) :258-266

[5] Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications [J].

Albertsen, Louise ;

Andersen, Julie J. ;

Paulsson, Johan F. ;

Thomsen, Jens K. ;

Norrild, Jens C. ;

Stromgaard, Kristian .

ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (12) :1228-1232

[6] MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study [J].

Ambery, Philip ;

Parker, Victoria E. ;

Stumvoll, Michael ;

Posch, Maximilian G. ;

Heise, Tim ;

Plum-Moerschel, Leona ;

Tsai, Lan-Feng ;

Robertson, Darren ;

Jain, Meena ;

Petrone, Marcella ;

Rondinone, Cristina ;

Hirshberg, Boaz ;

Jermutus, Lutz .

LANCET, 2018, 391 (10140) :2607-2618

[7]

[Anonymous], 2000, World Health Organ Tech Rep Ser, V894, pi

[8] The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice [J].

Baggio, Laurie L. ;

Ussher, John R. ;

McLean, Brent A. ;

Cao, Xiemin ;

Kabir, M. Golam ;

Mulvihill, Erin E. ;

Mighiu, Alexandra S. ;

Zhang, Hangjun ;

Ludwig, Andreas ;

Seeley, Randy J. ;

Heximer, Scott P. ;

Drucker, Daniel J. .

MOLECULAR METABOLISM, 2017, 6 (11) :1339-1349

[9] Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure [J].

Baggio, LL ;

Huang, QL ;

Brown, TJ ;

Drucker, DJ .

GASTROENTEROLOGY, 2004, 127 (02) :546-558

[10]

BATAILLE D, 1981, CR ACAD SCI III-VIE, V293, P323

← 1 2 3 4 5 6 7 8 9 10 →